Lawsuit Alert: Investors who lost money with shares of Verve Therapeutics, Inc. (NASDAQ: VERV) should contact the Shareholders Foundation

An investor, who purchased shares of Verve Therapeutics, Inc. (NASDAQ: VERV), filed a lawsuit over alleged violations of Federal Securities Laws by Verve Therapeutics, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Verve Therapeutics, Inc. (NASDAQ: VERV) have certain options and for certain investors are short and strict deadlines running. Deadline: October 28, 2024. NASDAQ: VERV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Cambridge, MA based Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. Verve Therapeutics, Inc. reported that its annual Total Revenue rose from $1.94 million in 2022 to $11.75 million in 2023, and that its Net Loss increased from $157.38 million in 2022 to $200.06 million in 2023.

On April 2, 2024, Verve Therapeutics, Inc disclosed that the Heart-1 clinical trial would be halted due to an adverse event in an individual who had been dosed at 0.45 mg/kg of VERVE-101, and that the LNP delivery system was to blame.

The same day Bloomberg published an article and according to the article, the Company "cited safety concerns for pausing enrollment in a study of its gene-editing treatment for people with high cholesterol, delivering a setback to the promising new field of medicine."

Shares of Verve Therapeutics, Inc. (NASDAQ: VERV) declined from $19.34 per share on February 29, 2024, to $4.30 per share on August 14, 2024.

The plaintiff claims that between August 9, 2022 and April 1, 2024, the defendants made false and/or misleading statements and/or failed to disclose, among other things, that defendants did not fully disclose the circumstances under which the Heart-1 Phase 1b clinical trial (the "Heart-1 Trial") of VERVE-101 would be halted (VERVE-101 is an investigational gene editing medicine designed to be a single course treatment that permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol (LDL-C)), that the defendants overstated the potential benefits of its proprietary lipid nanoparticle (LNP) delivery system, and that as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times

Those who purchased shares of Verve Therapeutics, Inc. (NASDAQ: VERV) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.